Audentes Therapeutics, Inc. (BOLD) formed multiple top with $35.23 target or 3.00% above today’s $34.20 share price. Audentes Therapeutics, Inc. (BOLD) has $1.26 billion valuation. The stock increased 1.63% or $0.55 during the last trading session, reaching $34.2. About 300,838 shares traded. Audentes Therapeutics, Inc. (NASDAQ:BOLD) has risen 72.67% since May 12, 2017 and is uptrending. It has outperformed by 61.12% the S&P500.
Among 9 analysts covering Lexicon Pharmaceuticals (NASDAQ:LXRX), 4 have Buy rating, 2 Sell and 3 Hold. Therefore 44% are positive. Lexicon Pharmaceuticals had 24 analyst reports since August 4, 2015 according to SRatingsIntel. JP Morgan downgraded Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) rating on Monday, August 10. JP Morgan has “Overweight” rating and $14 target. The firm earned “Buy” rating on Friday, October 7 by H.C. Wainwright. Wedbush maintained the shares of LXRX in report on Monday, August 7 with “Buy” rating. The stock has “Hold” rating by Cowen & Co on Tuesday, August 1. Wedbush maintained it with “Buy” rating and $4000 target in Monday, May 7 report. The firm earned “Buy” rating on Thursday, October 5 by Wedbush. The firm earned “Buy” rating on Thursday, November 30 by Wedbush. The stock of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) has “Hold” rating given on Friday, February 23 by Needham. Wedbush maintained Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) on Monday, April 16 with “Outperform” rating. The stock has “Buy” rating by Stifel Nicolaus on Friday, September 8. See Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) latest ratings:
07/05/2018 Broker: Wedbush Rating: Buy New Target: $40.0000 Maintain
04/05/2018 Broker: Citigroup Old Rating: Buy New Rating: Buy Old Target: $28 New Target: $27 Maintain
04/05/2018 Broker: Stifel Nicolaus Old Rating: Buy New Rating: Buy Old Target: $25 New Target: $24 Maintain
16/04/2018 Broker: Wedbush Old Rating: Outperform New Rating: Outperform Old Target: $38 New Target: $40 Maintain
12/03/2018 Broker: Wedbush Rating: Buy New Target: $38.0 Maintain
23/02/2018 Broker: Needham Rating: Hold Downgrade
14/02/2018 Broker: J.P. Morgan Rating: Sell New Target: $10.0 Downgrade
14/02/2018 Broker: JP Morgan Old Rating: Neutral New Rating: Underweight Downgrade
30/11/2017 Broker: Wedbush Rating: Buy New Target: $38.0 Maintain
More notable recent Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) news were published by: Seekingalpha.com which released: “Biotech Forum: The Week Ahead” on May 07, 2018, also Seekingalpha.com with their article: “Lexicon Pharmaceuticals Still Has Much To Prove” published on May 04, 2018, Nasdaq.com published: “New Research: Key Drivers of Growth for EW Scripps, Switch, Realogy, The Charles Schwab, CenterPoint Energy, and …” on May 11, 2018. More interesting news about Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) were released by: Seekingalpha.com and their article: “Lexicon Pharmaceuticals’ (LXRX) CEO Lonnel Coats on Q1 2018 Results – Earnings Call Transcript” published on May 03, 2018 as well as Nasdaq.com‘s news article titled: “Lexicon Pharmaceuticals to Present at Upcoming Investor Conference” with publication date: May 01, 2018.
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases. The company has market cap of $1.00 billion. The firm offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with SSA therapy in adults. It currently has negative earnings. The Company’s orally-delivered small molecule drug candidates under development comprise Sotagliflozin that is in Phase 3 clinical trials for use in the treatment of type 1 and type 2 diabetes; LX2761, which is in Phase 1 development for use in the treatment of diabetes; and LX9211 for use as a treatment for neuropathic pain.
The stock increased 1.93% or $0.18 during the last trading session, reaching $9.49. About 572,030 shares traded. Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) has declined 43.19% since May 12, 2017 and is downtrending. It has underperformed by 54.74% the S&P500.